(Date:11/24/2009)...Call/-HardtoTreatDiseases(HTDS; http://www.htdsmed...,isprovidingthisbriefupdatetoitsfollowersandshareh...Ustemcellcompanyandmergerdiscussions.Thisrelatesto...companymade. http://www.pinksheets.com/pink/quote/...caBiochemarealsodiscussingonexpandingtheresearchto...
(Date:11/24/2009)...TheAmericanDentalAssociation(ADA)hassignedanagreem...aspartofapilotprogramtoimprovetheoralhealthinunder...oordinator(CDHC)isamemberofthedentalhealthteamwhow...dentalcaretoimprovetheiroralhealth. ,, TheCDHCp...--includingscreeningsandfluoridetreatments.However...
(Date:11/24/2009)...Thereisanewgameintownwhenitcomestodealingwithalcoh...ealisticstrategieswheretraditionalapproachestoalco...roupcalledHAMS--HarmReduction,AlcoholAbstinenceand...portandinformationalgroupforpeoplewhodrinkalcohol....lismtellsusthatonly7%ofpeoplewithanalcoholprobleme...
(Date:11/24/2009)...N,LA,ME,NE,NDandSD ,, ALEXANDRIA,Va.,Nov.24/PR...onSaturdaytotakeupthehealthcarereformlegislation,t...mpaigntargetingSenatorsinninestates-Alaska,Arkansa...kota,andSouthDakota. ,, The$2.0millionadbuyhigh...reportwhichconfirmscutstoMedicareofhalfatrilliondo...
(Date:11/24/2009)...LifeInsuranceCompanyofAmerica(Guardian),oneofthela...eebenefitsforsmallandmid-sizedcompanies,todayannou...surancecoverageguidelinesformammographyscreenings....ocietyandAmericanMedicalAssociation(AMA)recommenda....S.PreventiveServicesTaskForcerecommendedincreasin...
Breaking Medicine News(10 mins):Health News:Hard To Treat Diseases (HTDS) Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger 2Health News:Hard To Treat Diseases (HTDS) Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger 3Health News:ADA Launches Community Dental Health Coordinator Pilot Program at Temple University 2Health News:Harm Reduction for Alcohol: An Idea Whose Time Has Arrived 2Health News:Senate Votes to Proceed - 60 Plus Announces New 9 State TV Campaign Targeted at Senators to Protect Medicare 2Health News:Senate Votes to Proceed - 60 Plus Announces New 9 State TV Campaign Targeted at Senators to Protect Medicare 3(Date:11/24/2009)...,, RALEIGH,N.C.,Nov.24/PRNewswire/--Pharmace...ingsolutionsforthepharmaceuticalandbiotechindustry...italMarketplace .Thenew HospitalMarketplace e-cour...Excellence(TM) series,acomprehensiveseriesofe-cour...dmanagedmarketsknowledgeforcommercialprofessionals...
(Date:11/24/2009)...,, HOLMDEL,N.J.,Nov.24/PRNewswire/--SpartaSy...leaderinenterprisequalityandcompliancesolutions,to...ingconsumerproductcompanyandtheparentcompanyforglo...ivewithTrackWiseEnterpriseQualityManagementSystem(...oharmonizeandstreamlinequalityoperationsthatinclud...
(Date:11/24/2009)...,, SALTLAKECITY,Nov.24/PRNewswire/-- Infinit...thelaunchofanewonlinevisiontherapyprogrameyeQ,thes...n-officetherapymethods. ,, eyeQ wasintroduceda...ustrypresidentelect,Dr.BradHabermehlbelievesthe ey...yLearningCenterinFlintMichigan.Itallowshispatients...
Breaking Medicine Technology:Pharmaceutical Institute Launches New Training Resource Focused on the Hospital Marketplace 2SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 2SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 3Infinite Mind Announces the Launch of a New Online Vision Therapy Program eyeQ 2At the fungal farmers market only the best cyanobacteria are for sale 9661 1At the fungal farmers market only the best cyanobacteria are for sale 9661 2Nick Jonas to Speak on Juvenile Diabetes at National Press Club August 24 55055 1Nick Jonas to Speak on Juvenile Diabetes at National Press Club August 24 55055 2Cell Therapeutics Inc Announces Closing of Registered Offering of 2430 Million of Preferred Stock and Warrants 13648 1Cell Therapeutics Inc Announces Closing of Registered Offering of 2430 Million of Preferred Stock and Warrants 13648 2...lood pressure reductions of 30.8 mm Hg,systolic bl...pressure (DBP),at five weeks and 21.1/19.3 mm Hg (... of patients with severe hypertension, AVAL...4.6 mm Hg (SBP/DBP), at 8 weeks, and 22.1/11.6 mm...ectively for irbesartan and HCTZ alone, in a study...
...Proprietary siRNA Molecule in Acute .... 19 Quark Pharmaceuticals, Inc., a,development-s... and,developing novel RNA interference-based thera...temic dosing in humans of its proprietary product,... developed by Quark for,the treatment of Acute Ren...
Other Medicine Technology:Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 2Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 3Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 4Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 5Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 6Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 7Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 2Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 3Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 4...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
Medicine Products: